Rapamycin inhibits some, but not all, activities of mTOR. Recently we and others demonstrated that pan-mTOR inhibitors, known also as dual mTORC1/C2 inhibitors, suppress senescent phenotype. As a ...

15 Due to the frequent involvement of PI3K, mTOR and NOTCH pathways in T-ALL, we have explored the effects of combined inhibition of these pathways. We find that PI3K/mTOR inhibition can lead to ...

Soon after rapamycin, the first mTOR inhibitor, emerged in 1990s as a potential treatment against unwanted cell proliferation, many cancer experts had hoped emerging drugs targeting mTOR would ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the mTOR inhibitors in the oncology market. The report includes a detailed analysis of the pipeline ...

Anti-cancer drugs called mTOR inhibitors slow the growth of cancer cells but show limited ability to cause cancer cell death. A new studies explain why. Anti-cancer drugs called mTOR inhibitors ...

Mammalian target of rapamycin (mTOR) inhibitors could be associated with acute nephrotoxicity, according to French researchers. The team describes 4 cancer patients who developed severe acute ...

What mTOR inhibition seems to do is “make a lot of aging organ systems function a little better and decline a little slower, but ‘a little better’ and ‘a little slower’ is tough to prove ...

In cohort 1, the most common first-line treatments were tyrosine kinase inhibitors (TKI; 78.8%), followed by mammalian target of rapamycin (mTOR) inhibitors (12.4%), the investigators reported in ...